<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "8: operations", fill: "#ff43a4"},
{source: "8: operations", target: "8: technology", fill: "#ff43a4"},
{source: "8: technology", target: "8: preclinical studies", fill: "#ff43a4"},
{source: "8: preclinical studies", target: "8: clinical trials", fill: "#ff43a4"},
{source: "8: clinical trials", target: "8: candidates", fill: "#ff43a4"},
{source: "8: operations", target: "9: yet demonstrated", fill: "#29ab87"},
{source: "9: yet demonstrated", target: "9: regulatory approval formulate", fill: "#29ab87"},
{source: "9: regulatory approval formulate", target: "9: manufacture", fill: "#29ab87"},
{source: "9: manufacture", target: "9: drug candidates on", fill: "#29ab87"},
{source: "9: drug candidates on", target: "9: commercial scale", fill: "#29ab87"},
{source: "9: commercial scale", target: "9: conduct sales", fill: "#29ab87"},
{source: "9: conduct sales", target: "9: marketing activities", fill: "#29ab87"},
{source: "9: yet demonstrated", target: "14: Contents ", fill: "#a1caf1"},
{source: "14: Contents ", target: "14: commercializing one", fill: "#a1caf1"},
{source: "14: commercializing one", target: "14: drug candidates", fill: "#a1caf1"},
{source: "14: drug candidates", target: "14: use significant cash resources", fill: "#a1caf1"},
{source: "14: use significant cash resources", target: "14: operations", fill: "#a1caf1"},
{source: "14: operations", target: "14: foreseeable future", fill: "#a1caf1"},
{source: "14: Contents ", target: "16: expenses will increase", fill: "#cfb53b"},
{source: "16: expenses will increase", target: "16: substantially", fill: "#cfb53b"},
{source: "16: substantially", target: "16: conduct preclinical", fill: "#cfb53b"},
{source: "16: conduct preclinical", target: "16: clinical trials", fill: "#cfb53b"},
{source: "16: clinical trials", target: "16: candidates", fill: "#cfb53b"},
{source: "16: candidates", target: "16: seek regulatory approvals", fill: "#cfb53b"},
{source: "16: seek regulatory approvals", target: "16: drug candidates", fill: "#cfb53b"},
{source: "16: drug candidates", target: "16: formulate manufacture", fill: "#cfb53b"},
{source: "16: formulate manufacture", target: "16: commercialize", fill: "#cfb53b"},
{source: "16: commercialize", target: "16: additional internal systems", fill: "#cfb53b"},
{source: "16: additional internal systems", target: "16: new infrastructure", fill: "#cfb53b"},
{source: "16: new infrastructure", target: "16: technologies", fill: "#cfb53b"},
{source: "16: technologies", target: "16: technology", fill: "#cfb53b"},
{source: "16: technology", target: "16: intellectual property", fill: "#cfb53b"},
{source: "16: intellectual property", target: "16: hire additional personnel", fill: "#cfb53b"},
{source: "16: expenses will increase", target: "26: raise additional funds", fill: "#00563f"},
{source: "26: raise additional funds", target: "26: development", fill: "#00563f"},
{source: "26: development", target: "26: drug candidates", fill: "#00563f"},
{source: "26: raise additional funds", target: "START_HERE", fill: "#00563f"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Investment Banking and Brokerage</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Application Software</td>
    </tr>
    <tr>
      <td>Independent Power Producers and Energy Traders</td>
    </tr>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
    <tr>
      <td>Food Distributors</td>
    </tr>
    <tr>
      <td>Trading Companies and Distributors</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
    <tr>
      <td>Health Care Supplies</td>
    </tr>
    <tr>
      <td>Health Care</td>
    </tr>
    <tr>
      <td>Health Care Equipment and Services</td>
    </tr>
    <tr>
      <td>Managed Health Care</td>
    </tr>
    <tr>
      <td>Automobile Manufacturers</td>
    </tr>
    <tr>
      <td>Motorcycle Manufacturers</td>
    </tr>
    <tr>
      <td>Pharmaceuticals Biotechnology and Life Sciences</td>
    </tr>
    <tr>
      <td>Biotechnology</td>
    </tr>
    <tr>
      <td>Drug Retail</td>
    </tr>
    <tr>
      <td>Automobiles and Components</td>
    </tr>
    <tr>
      <td>Electrical Components and Equipment</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Economic</td>
    </tr>
    <tr>
      <td>Ease</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Material Aid</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Leadership</td>
    </tr>
    <tr>
      <td>Disapprove</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Political reform</td>
    </tr>
    <tr>
      <td>Rights</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Military blockade</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Reward</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Complain</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Request</td>
    </tr>
    <tr>
      <td>Consult</td>
    </tr>
    <tr>
      <td>Yield position</td>
    </tr>
    <tr>
      <td>Sanction</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
    <tr>
      <td>Reject</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Empathize</td>
    </tr>
    <tr>
      <td>Pessimistic comment</td>
    </tr>
    <tr>
      <td>Formally complain</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
    <tr>
      <td>Rally support</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Clinical_trial">Clinical trial</a></td>
      <td>Clinical trials are experiments or observations done in clinical research. Such prospective biomedical or behavioral research studies on human participants are designed to answer specific questions about biomedical or behavioral interventions, including new treatments (such as novel vaccines, drugs, dietary choices, dietary supplements, and medical devices) and known interventions that warrant further study and comparison.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/ClinicalTrials.gov">ClinicalTrials.gov</a></td>
      <td>ClinicalTrials.gov is a registry of clinical trials. It is run by the United States National Library of Medicine (NLM) at the National Institutes of Health, and is the largest clinical trials database, holding registrations from over 329,000 trials from 209 countries.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Adaptive_clinical_trial">Adaptive clinical trial</a></td>
      <td>An adaptive clinical trial is a dynamic clinical trial that evaluates a medical device or treatment by observing participant outcomes (and possibly other measures, such as side-effects) on a prescribed schedule, and, uniquely, modifying parameters of the trial protocol in accord with those observations. This is in contrast to traditional randomized clinical trials (RCTs) that are static in their protocol and do not modify any parameters until the trial is completed.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Randomized_controlled_trial">Randomized controlled trial</a></td>
      <td>A randomized controlled trial (or randomized control trial; RCT) is a form of scientific experiment used to control factors not under direct experimental control. Examples of RCTs are clinical trials that compare the effects of drugs, surgical techniques, medical devices, diagnostic procedures or other medical treatments.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Pragmatic_clinical_trial">Pragmatic clinical trial</a></td>
      <td>A pragmatic clinical trial (PCT), sometimes called a practical clinical trial (PCT), is a clinical trial that focuses on correlation between treatments and outcomes in real-world health system practice rather than focusing on proving causative explanations for outcomes, which requires extensive deconfounding with inclusion and exclusion criteria so strict that they risk rendering the trial results irrelevant to much of real-world practice.\n\n\n== Examples ==\nA typical example is that an anti-diabetic medication in the real world will often be used in people with (latent or apparent) diabetes-induced kidney problems, but if a study of its efficacy and safety excluded some subsets of people with kidney problems (to escape confounding), the study's results may not reflect well what will actually happen in broad practice.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Monitoring_in_clinical_trials">Monitoring in clinical trials</a></td>
      <td>Clinical monitoring is the oversight and administrative efforts that monitor a participant's health and efficacy of the treatment during a clinical trial. Both independent and government-run grant-funding agencies, such as the National Institutes of Health (NIH) and the World Health Organization (WHO), require data and safety monitoring protocols for Phase I and II clinical trials conforming to their standards.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Clinical_trials_in_India">Clinical trials in India</a></td>
      <td>Clinical trials in India refers to clinical research in India in which researchers test drugs and other treatments on research participants. NDCTR 2019 and section 3.7.1 to 3.7.3 of ICMR guidelines requires that all researchers conducting a clinical trial must publicly document it in the Clinical Trials Registry - India.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Clinical_trial_management_system">Clinical trial management system</a></td>
      <td>A Clinical Trial Management System (CTMS) is a software system used by biotechnology and pharmaceutical industries to manage clinical trials in clinical research. The system maintains and manages planning, performing and reporting functions, along with participant contact information, tracking deadlines and milestones.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Candidate">Candidate</a></td>
      <td>A candidate, or nominee, is the prospective recipient of an award or honor, or a person seeking or being considered for some kind of position; for example:\n\nto be elected to an office — in this case a candidate selection procedure occurs.\nto receive membership in a  group"Nomination" is part of the process of selecting a candidate for either election to an office by a political party, or the bestowing of an honor or award.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Candidates_of_the_2022_Australian_federal_election">Candidates of the 2022 Australian federal election</a></td>
      <td>This is a list of confirmed candidates in ballot paper order for the 2022 Australian federal election.At the close of nominations a total of 1,624 candidates had stood for election, of whom 1,203 were House of Representatives candidates and 421 were Senate candidates.\n\n\n== Retiring members ==\nThe seat of Spence (SA) was vacant following the resignation of Nick Champion (Labor) on 22 February 2022 to contest the South Australian state election.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Write-in_candidate">Write-in candidate</a></td>
      <td>A write-in candidate is a candidate whose name does not appear on the ballot but seeks election by asking voters to cast a vote for the candidate by physically writing in the person's name on the ballot. Depending on electoral law it may be possible to win an election by winning a sufficient number of such write-in votes, which count equally as if the person was formally listed on the ballot.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Candidates_Tournament">Candidates Tournament</a></td>
      <td>The Candidates Tournament (or in some periods Candidates Matches) is a chess tournament organized by FIDE, chess's international governing body, since 1950, as the final contest to determine the challenger for the World Chess Championship. The winner of the Candidates earns the right to a match for the World Championship against the incumbent World Champion.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Perennial_candidate">Perennial candidate</a></td>
      <td>A perennial candidate is a political candidate who frequently runs for elected office and rarely, if ever, wins. Perennial candidates' existence lies in the fact that in some countries, there are no laws that limit a number of times a person can run for office, or laws that impose a non-negligible financial penalty on registering to run for election.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Candidates_Tournament_2022">Candidates Tournament 2022</a></td>
      <td>The 2022 Candidates Tournament is an upcoming eight-player chess tournament, to decide the challenger for the World Chess Championship 2023. The tournament is scheduled to take place at the Palace of Santoña in Madrid, Spain from June 16 to July 5, 2022, with the World Championship to follow in early 2023.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Officer_candidate">Officer candidate</a></td>
      <td>Officer candidate or officer aspirant (OA) is a rank in some militaries of the world that is an appointed position while a person is in training to become an officer.  More often than not, an officer candidate was a civilian who applied to join the military directly as an officer.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Drug_discovery">Drug discovery</a></td>
      <td>In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which new candidate medications are discovered.Historically, drugs were discovered by identifying the active ingredient from traditional remedies or by serendipitous discovery, as with penicillin. More recently, chemical libraries of synthetic small molecules, natural products or extracts were screened in intact cells or whole organisms to identify substances that had a desirable therapeutic effect in a process known as classical pharmacology.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Drug_metabolism">Drug metabolism</a></td>
      <td>Drug metabolism is the metabolic breakdown of drugs by living organisms, usually through specialized enzymatic systems. More generally, xenobiotic metabolism (from the Greek xenos "stranger"  and biotic "related to living beings") is the set of metabolic pathways that modify the chemical structure of xenobiotics, which are compounds foreign to an organism's normal biochemistry, such as any drug or poison.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Drug_development">Drug development</a></td>
      <td>Drug development is the process of bringing a new pharmaceutical drug to the market once a lead compound has been identified through the process of drug discovery.  It includes preclinical research on microorganisms and animals, filing for regulatory status, such as via the United States Food and Drug Administration for an investigational new drug to initiate clinical trials on humans, and may include the step of obtaining regulatory approval with a new drug application to market the drug.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercialization">Commercialization</a></td>
      <td>Commercialization or commercialisation is the process of introducing a new product or production method into commerce—making it available on the market. The term often connotes especially entry into the mass market (as opposed to entry into earlier niche markets), but it also includes a move from the laboratory into (even limited) commerce.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercialization_of_love">Commercialization of love</a></td>
      <td>The notion of commercialization of love, that is not to be confused with prostitution (the commercialization of sexual activity), involves the definitions of romantic love and consumerism.\n\n\n== Sociological development ==\nThe commercialization of love is the ongoing process of infiltration of commercial and economical stimuli in the daily life of lovers and the association of monetary and non-monetary symbols and commodities in the love relationships.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercial_use_of_space">Commercial use of space</a></td>
      <td>Commercial use of space is the provision of goods or services of commercial value by using equipment sent into Earth orbit or outer space.  This phenomenon – aka Space Economy (or New Space Economy) – is accelerating cross-sector innovation processes combining the most advanced space and digital technologies to develop a broad portfolio of space-based services.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Santaris_Pharma">Santaris Pharma</a></td>
      <td>Santaris Pharma A/S was a biopharmaceutical company founded in 2003 in Copenhagen, Denmark. The company also had a branch in San Diego, California that opened in 2009.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/COVID-19_drug_development">COVID-19 drug development</a></td>
      <td>COVID-19 drug development is the research process to develop preventative therapeutic prescription drugs that would alleviate the severity of coronavirus disease 2019 (COVID-19). From early 2020 through 2021, several hundred drug companies, biotechnology firms, university research groups, and health organizations were developing therapeutic candidates for COVID-19 disease in various stages of preclinical or clinical research (506 total candidates in April 2021), with 419 potential COVID-19 drugs in clinical trials, as of April 2021.As early as March 2020, the World Health Organization (WHO), European Medicines Agency (EMA), US Food and Drug Administration (FDA), and the Chinese government and drug manufacturers were coordinating with academic and industry researchers to speed development of vaccines, antiviral drugs, and post-infection therapies.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/The_Managed_Heart">The Managed Heart</a></td>
      <td>The Managed Heart: Commercialization of Human Feeling, by Arlie Russell Hochschild, was first published in 1983. A 20th Anniversary edition with a new afterword added by the author was published in 2003.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Kendrick_Lamar">Kendrick Lamar</a></td>
      <td>Kendrick Lamar Duckworth (born June 17, 1987) is an American rapper, songwriter, and record producer. He is often cited as one of the most influential rappers of his generation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercial_software">Commercial software</a></td>
      <td>Commercial software, or seldom payware, is a computer software that is produced for sale or that serves commercial purposes. Commercial software can be proprietary software or free and open-source software.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercialization_of_the_Internet">Commercialization of the Internet</a></td>
      <td>The commercialization of the Internet refers to the creation and management of online services principally for financial gain. It typically involves the increasing monetization of network services and consumer products mediated through the varied use of Internet technologies.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Windows_Notepad">Windows Notepad</a></td>
      <td>Windows Notepad is a simple text editor for Windows; it creates and edits plain text documents. First released in 1983 to commercialize the computer mouse in MS-DOS, Notepad has been part of every version of Windows ever since.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Sustainable_development">Sustainable development</a></td>
      <td>Sustainable development is an organizing principle for meeting human development goals while also sustaining the ability of natural systems to provide the natural resources and ecosystem services on which the economy and society depend. The desired result is a state of society where living conditions and resources are used to continue to meet human needs without undermining the integrity and stability of the natural system.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arrested_Development">Arrested Development</a></td>
      <td>Arrested Development is an American television sitcom created by Mitchell Hurwitz, which originally aired on Fox for three seasons from  2003 to 2006, followed by a two-season revival on Netflix from 2013 to 2019. The show follows the Bluths, a formerly wealthy dysfunctional family.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Research_and_development">Research and development</a></td>
      <td>Research and development (R&amp;D or R+D), known in Europe as research and technological development (RTD), is the set of innovative activities undertaken by corporations or governments in developing new services or products, and improving existing ones. Research and development constitutes the first stage of development of a potential new service or the production process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Personal_development">Personal development</a></td>
      <td>Personal development or self improvement consists of activities that develop a person's capabilities and potential, build human capital, facilitate employability, and enhance quality of life and the realization of dreams and aspirations. Personal development may take place over the course of an individual's entire lifespan and is not limited to one stage of a person's life.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Prenatal_development">Prenatal development</a></td>
      <td>Prenatal development (from Latin  natalis 'relating to birth') includes the development of the embryo and of the foetus during a viviparous animal's gestation. Prenatal development starts with fertilization, in the germinal stage of embryonic development, and continues in fetal development until birth.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>PAIN THERAPEUTICS INC      Item 1A Risk Factors          Our future operating results <font color="blue">may vary <font color="blue">substantially</font> from</font> anticipated results     due  to a number of factors, many of which are beyond our control</td>
    </tr>
    <tr>
      <td>The     following discussion <font color="blue">highlights</font> some of these factors and the possible     impact  of  these  <font color="blue">factors on future</font> results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>You should     <font color="blue">carefully</font> consider these factors before making an <font color="blue"><font color="blue">investment</font> decision</font></td>
    </tr>
    <tr>
      <td>If     any  of  the <font color="blue">following factors</font> actually occur, our business, financial     condition or results of <font color="blue">operations</font> could be harmed</td>
    </tr>
    <tr>
      <td>In that case, the price     of our <font color="blue"><font color="blue">common stock</font> could decline</font>, and you could experience losses on your     <font color="blue">investment</font></td>
    </tr>
    <tr>
      <td><font color="blue">Risks Relating </font>to our Financial Position and Need for Financing          Our operating <font color="blue">history may</font> make it <font color="blue">difficult</font> for you to evaluate our business     to date and to assess its <font color="blue">future viability</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">operations</font> to date have been limited to     organizing and staffing our company, acquiring, developing and securing our     <font color="blue">technology</font> and undertaking <font color="blue">preclinical studies</font> and <font color="blue"><font color="blue">clinical trial</font>s</font> of our     drug  <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>We  have not <font color="blue">yet <font color="blue">demonstrate</font>d</font> our ability to obtain     <font color="blue"><font color="blue">regulatory</font> approval</font>, formulate and <font color="blue">manufacture</font> our drug <font color="blue">candidates</font> on a     <font color="blue">commercial scale</font> or <font color="blue">conduct sales</font> and <font color="blue">marketing activities</font></td>
    </tr>
    <tr>
      <td>Consequently,     any <font color="blue">predictions</font> you make about our future success or viability may not be as     accurate as they could be if we had a longer operating history</td>
    </tr>
    <tr>
      <td>We have a history of losses and expect to incur substantial losses and     negative operating <font color="blue">cash flows</font> for the <font color="blue">foreseeable future</font></td>
    </tr>
    <tr>
      <td>We have <font color="blue">incurred net losses each year since</font> our inception</td>
    </tr>
    <tr>
      <td>As a result of     ongoing operating losses, we had an <font color="blue">accumulated</font> deficit of dlra142dtta7 million as     <font color="blue">of December </font>31, 2005</td>
    </tr>
    <tr>
      <td>Even if we succeed in developing and                                           11     ______________________________________________________________________    [34]Table of <font color="blue">Contents       </font><font color="blue"><font color="blue">commercializing</font> one</font> or more of our drug <font color="blue">candidates</font>, we expect to continue to     <font color="blue">use <font color="blue">significant</font> cash resources</font> in our <font color="blue">operations</font> for the <font color="blue">foreseeable future</font></td>
    </tr>
    <tr>
      <td>We recognized positive cash flow from <font color="blue">operations</font> in 2005 as a result of the     <font color="blue">upfront payment from</font> King</td>
    </tr>
    <tr>
      <td>We anticipate that our <font color="blue">expenses will increase</font>     <font color="blue">substantially</font> in the <font color="blue">foreseeable future</font> as we:           •   continue to <font color="blue">conduct preclinical</font> and <font color="blue"><font color="blue">clinical trial</font>s</font> for our drug     <font color="blue">candidates</font>;           •   <font color="blue">seek <font color="blue"><font color="blue">regulatory</font> approval</font>s</font> for our drug <font color="blue">candidates</font>;           •   develop, formulate, <font color="blue">manufacture</font> and <font color="blue">commercialize</font> our drug <font color="blue">candidates</font>;           •   implement <font color="blue"><font color="blue">additional</font> internal systems</font> and develop <font color="blue">new infrastructure</font>;           •   acquire or in-license <font color="blue">additional</font> products or <font color="blue">technologies</font>, or expand     the use of our <font color="blue">technology</font>;           •   maintain, defend and expand the scope of our <font color="blue">intellectual property</font>;     and           •   <font color="blue">hire <font color="blue">additional</font> personnel</font></td>
    </tr>
    <tr>
      <td>We  will need to <font color="blue">generate <font color="blue">significant</font> revenues</font> to achieve and maintain     <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>If we <font color="blue">cannot <font color="blue">successfully</font></font> develop, obtain <font color="blue"><font color="blue">regulatory</font> approval</font>     for and <font color="blue">commercialize</font> our drug <font color="blue">candidates</font>, we will not be able to generate     <font color="blue">such revenues</font> or achieve <font color="blue">profitability</font> in the future</td>
    </tr>
    <tr>
      <td>Our failure to achieve     or maintain <font color="blue">profitability</font> would have a material <font color="blue">adverse <font color="blue">impact on</font></font> the market     price of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>If we <font color="blue">cannot raise <font color="blue">additional</font> capital on</font> acceptable terms, we may be unable     to complete planned <font color="blue"><font color="blue">clinical trial</font>s</font> of any or some of our drug <font color="blue">candidates</font> or     to <font color="blue">pursue attractive</font> business <font color="blue">opportunities</font></td>
    </tr>
    <tr>
      <td>We have funded all of our <font color="blue">operations</font> and <font color="blue"><font color="blue">capital <font color="blue">expenditure</font></font>s with</font> the     <font color="blue">proceeds from</font> our public and <font color="blue">private stock offerings</font></td>
    </tr>
    <tr>
      <td>We expect that our     current cash, cash equivalents and <font color="blue">marketable securities on hand will</font> be     sufficient to meet our working capital and <font color="blue">capital <font color="blue">expenditure</font></font> needs for at     least the <font color="blue">next twelve months</font></td>
    </tr>
    <tr>
      <td>However, we may need to <font color="blue">raise <font color="blue">additional</font> funds</font>     within such twelve-month period or thereafter and <font color="blue"><font color="blue">additional</font> financing may</font>     not  be <font color="blue">available on</font> favorable terms, if at all</td>
    </tr>
    <tr>
      <td>Even if we succeed in     <font color="blue">selling <font color="blue">additional</font> securities</font> to <font color="blue">raise funds</font>, our <font color="blue">existing <font color="blue">stockholders</font></font>’     <font color="blue">ownership percentage would</font> be reduced and <font color="blue">new investors may demand rights</font>,     <font color="blue">preferences</font> or <font color="blue">privileges senior</font> to those of <font color="blue">existing <font color="blue">stockholders</font></font></td>
    </tr>
    <tr>
      <td>If we     raise  <font color="blue">additional</font>  capital  through  strategic  alliance  and  license     <font color="blue">arrangements</font>,  we  may  have  to  trade  our rights to our <font color="blue">technology</font>,     <font color="blue">intellectual property</font> or drug <font color="blue">candidates</font> to others in such <font color="blue">arrangements</font> on     terms that may not be favorable to us</td>
    </tr>
    <tr>
      <td>If  we determine that we need to <font color="blue">raise <font color="blue">additional</font> funds</font> and we are not     successful  in  doing  so,  we  may be unable to complete the clinical     <font color="blue">development</font> of some or all of our drug <font color="blue">candidates</font> or to seek or obtain FDA     approval of our drug <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>We then could be forced to <font color="blue">discontinue</font>     product <font color="blue">development</font>, <font color="blue">enter into</font> a <font color="blue"><font color="blue">relationship</font> with</font> a <font color="blue">strategic partner</font>     earlier than currently intended, reduce sales and <font color="blue">marketing efforts</font> or     <font color="blue">forego attractive</font> business <font color="blue">opportunities</font></td>
    </tr>
    <tr>
      <td>Clinical and <font color="blue">Regulatory </font>Risks          If we fail to obtain the <font color="blue">necessary</font> <font color="blue"><font color="blue">regulatory</font> approval</font>s, we will not be     allowed to <font color="blue">commercialize</font> our drug <font color="blue">candidates</font>, and we will not generate     <font color="blue">product revenues</font></td>
    </tr>
    <tr>
      <td><font color="blue">Satisfaction </font>of all <font color="blue">regulatory</font> <font color="blue">requirements</font> typically takes many years, is     <font color="blue">dependent</font> upon the type, <font color="blue">complexity</font> and novelty of the <font color="blue">drug candidate</font>, and     requires  the  <font color="blue">expenditure</font>  of  substantial resources for research and     <font color="blue">development</font> and testing</td>
    </tr>
    <tr>
      <td>Our research and <font color="blue">clinical approaches may</font> not lead     to drugs that the FDA considers safe for humans and <font color="blue">effective</font> for indicated     uses we are studying</td>
    </tr>
    <tr>
      <td>The FDA may require us to conduct <font color="blue">additional</font> clinical     testing, in which case we would have to expend <font color="blue">additional</font> time and resources     and  would  likely  delay the date of <font color="blue">potentially</font> receiving <font color="blue">regulatory</font>     approval</td>
    </tr>
    <tr>
      <td>In particular, the FDA may require <font color="blue">additional</font> toxicology studies     for <font color="blue">certain excipients used</font> in Remoxy or any of our other drug <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">approval process may also</font>                                           12     ______________________________________________________________________    [35]Table of <font color="blue">Contents       </font>be  <font color="blue">delayed by</font> changes in <font color="blue">government</font> regulation, future <font color="blue">legislation</font> or     <font color="blue">administrative action</font> or changes in FDA policy that occur prior to or during     our <font color="blue">regulatory</font> review</td>
    </tr>
    <tr>
      <td>Delays in obtaining <font color="blue"><font color="blue">regulatory</font> approval</font>s will:           •   delay <font color="blue">commercialization</font> of, and <font color="blue">product revenues</font> from, our drug     <font color="blue">candidates</font>; and           •   diminish the <font color="blue">competitive <font color="blue">advantages</font></font> that we may have otherwise     enjoyed, <font color="blue">which would</font> have an adverse effect on our operating results and     <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>Even if we <font color="blue">comply with</font> all FDA <font color="blue">regulatory</font> <font color="blue">requirements</font>, we may never obtain     <font color="blue"><font color="blue">regulatory</font> approval</font> for any of our drug <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>If we fail to obtain     <font color="blue">regulatory</font>  approval for any of our drug <font color="blue">candidates</font> we will have fewer     <font color="blue">saleable products</font>, if any, and <font color="blue">corresponding</font> lower <font color="blue">product revenues</font>, if any</td>
    </tr>
    <tr>
      <td>Even if we receive <font color="blue"><font color="blue">regulatory</font> approval</font> of our drug <font color="blue">candidates</font>, such approval     may  involve  <font color="blue">limitations</font>  on the <font color="blue">indications</font> and <font color="blue">conditions</font> of use or     marketing claims we may make for our products</td>
    </tr>
    <tr>
      <td>Further, <font color="blue">later <font color="blue">discovery</font></font> of     <font color="blue"><font color="blue">previously</font> unknown problems</font> or <font color="blue"><font color="blue">adverse events</font> could</font> result in <font color="blue">additional</font>     <font color="blue">regulatory</font> <font color="blue">restrictions</font>, including withdrawal of products</td>
    </tr>
    <tr>
      <td>The FDA may also     require us to commit to perform lengthy <font color="blue">Phase IV </font>post-approval clinical     trials, for which we would have to expend <font color="blue">additional</font> resources, which could     have an adverse effect on our operating results and <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>In  <font color="blue">jurisdictions outside</font> the United States, we must receive marketing     <font color="blue">authorizations from</font> the appropriate <font color="blue">regulatory</font> <font color="blue">authorities</font> before we can     <font color="blue">commercialize</font> our drugs</td>
    </tr>
    <tr>
      <td><font color="blue">Regulatory </font>approval processes outside the United     States <font color="blue">generally</font> include all of the aforementioned <font color="blue">requirements</font> and risks     <font color="blue">associated with</font> FDA approval</td>
    </tr>
    <tr>
      <td>If  we  are  unable  to  design,  conduct and complete <font color="blue"><font color="blue">clinical trial</font>s</font>     <font color="blue">successfully</font>, we will not be able to obtain <font color="blue"><font color="blue">regulatory</font> approval</font> for our drug     <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>In order to obtain FDA approval for any of our drug <font color="blue">candidates</font>, we must     submit to the <font color="blue">FDA an NDA </font>that <font color="blue"><font color="blue">demonstrate</font>s</font> that the <font color="blue">drug candidate</font> is safe     and <font color="blue">effective</font> in humans for its <font color="blue">intended use</font></td>
    </tr>
    <tr>
      <td>This <font color="blue">demonstration</font> requires     <font color="blue"><font color="blue">significant</font> research</font> and animal tests, which are referred to <font color="blue">as preclinical</font>     studies, as well as human tests, which are referred to as <font color="blue"><font color="blue">clinical trial</font>s</font></td>
    </tr>
    <tr>
      <td><font color="blue">Our <font color="blue">Phase III </font></font><font color="blue"><font color="blue">clinical trial</font>s</font> may not <font color="blue">demonstrate</font> the safety or efficacy of     our drug <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>FDA <font color="blue"><font color="blue">guidelines</font> recommend</font> that the     efficacy of <font color="blue">new <font color="blue">painkillers</font></font> be <font color="blue">demonstrate</font>d in more <font color="blue">than one clinical model</font>     of  pain</td>
    </tr>
    <tr>
      <td>This means that even if one of our <font color="blue">Phase III </font><font color="blue"><font color="blue">clinical trial</font>s</font>     <font color="blue"><font color="blue">demonstrate</font>s</font> positive results for our drug <font color="blue">candidates</font>, we are likely to have     to <font color="blue">demonstrate</font> positive results in one or more <font color="blue">additional</font> <font color="blue">Phase III </font>clinical     <font color="blue">trials prior</font> to receiving <font color="blue">broad label</font> FDA approval for treatment of severe     <font color="blue">chronic pain</font></td>
    </tr>
    <tr>
      <td>Even if the results of our <font color="blue">Phase III </font><font color="blue"><font color="blue">clinical trial</font>s</font> are     positive, we may have to commit substantial time and <font color="blue">additional</font> resources to     conducting further <font color="blue">preclinical studies</font> and <font color="blue"><font color="blue">clinical trial</font>s</font> before we can     submit NDAs or obtain FDA approvals for our drug <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>Clinical trials are very expensive and <font color="blue">difficult</font> to design and implement, in     part because they are subject to rigorous <font color="blue">requirements</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">clinical trial</font>     process is also time consuming</td>
    </tr>
    <tr>
      <td>Furthermore, if <font color="blue">participating</font> patients in     <font color="blue"><font color="blue">clinical trial</font>s</font> suffer drug-related adverse reactions during the course of     such  clinical  trials, or if we or the FDA believe that <font color="blue">participating</font>     patients are being exposed to unacceptable <font color="blue">health risks</font>, we will have to     suspend or terminate our <font color="blue"><font color="blue">clinical trial</font>s</font></td>
    </tr>
    <tr>
      <td>Failure can occur at any stage of     the  <font color="blue"><font color="blue">clinical trial</font>s</font>, and we <font color="blue">could encounter problems</font> that cause us to     abandon or repeat <font color="blue"><font color="blue">clinical trial</font>s</font></td>
    </tr>
    <tr>
      <td>In  addition, <font color="blue">completion</font> of <font color="blue"><font color="blue">clinical trial</font>s</font> can be <font color="blue">delayed by</font> numerous     factors, including:           •   delays in identifying and <font color="blue">agreeing on</font> acceptable terms with     prospective <font color="blue">clinical trial</font> sites;           •   <font color="blue">slower than</font> expected rates of <font color="blue">patient recruitment</font> and <font color="blue">enrollment</font>;           •   increases in time required to complete monitoring of <font color="blue">patients during</font>     or after <font color="blue">participation</font> in a <font color="blue">clinical trial</font>; and           •   unexpected need for <font color="blue">additional</font> patient-related data</td>
    </tr>
    <tr>
      <td>13     ______________________________________________________________________    [36]Table of <font color="blue">Contents       </font>Any of these delays, if <font color="blue">significant</font>, could impact the timing, approval and     <font color="blue">commercialization</font> of our drug <font color="blue">candidates</font> and could <font color="blue">significant</font>ly increase     our overall costs of drug <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>Even if our <font color="blue"><font color="blue">clinical trial</font>s</font> are completed as planned, their results may not     support our <font color="blue">expectations</font> or <font color="blue">intended marketing</font> claims</td>
    </tr>
    <tr>
      <td>The <font color="blue"><font color="blue">clinical trial</font>s</font>     process  may fail to <font color="blue">demonstrate</font> that our drug <font color="blue">candidates</font> are safe and     <font color="blue">effective</font> for <font color="blue">indicated uses</font></td>
    </tr>
    <tr>
      <td>Such <font color="blue">failure would</font> cause us to abandon a drug     candidate and could delay <font color="blue">development</font> of other drug <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>Clinical <font color="blue">trial designs</font> that were <font color="blue">discussed with <font color="blue">authorities</font> prior</font> to their     <font color="blue"><font color="blue">commencement</font> may subsequently</font> be considered insufficient for <font color="blue">approval at</font> the     time of <font color="blue">application</font> for <font color="blue"><font color="blue">regulatory</font> approval</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">discuss with</font> and obtain guidance from <font color="blue">regulatory</font> <font color="blue">authorities</font> on certain     of our clinical <font color="blue">development</font> activities</td>
    </tr>
    <tr>
      <td>These <font color="blue">discussions</font> are not binding     <font color="blue"><font color="blue">obligations</font> on</font> the part of <font color="blue">regulatory</font> <font color="blue">authorities</font></td>
    </tr>
    <tr>
      <td><font color="blue">Regulatory </font><font color="blue">authorities</font>     <font color="blue">may revise previous guidance</font> or decide to <font color="blue">ignore previous guidance at</font> any     time during the course of our <font color="blue">clinical activities</font> or after the <font color="blue">completion</font> of     our <font color="blue"><font color="blue">clinical trial</font>s</font></td>
    </tr>
    <tr>
      <td>Even <font color="blue">with successful clinical safety</font> and <font color="blue">efficacy data</font>,     we may be required to conduct <font color="blue">additional</font>, expensive <font color="blue"><font color="blue">clinical trial</font>s</font> to     obtain <font color="blue"><font color="blue">regulatory</font> approval</font></td>
    </tr>
    <tr>
      <td><font color="blue">Developments </font><font color="blue">by <font color="blue"><font color="blue">competitor</font>s</font> may establish standards</font> of care that affect our     ability to conduct our <font color="blue"><font color="blue">clinical trial</font>s</font> as planned</td>
    </tr>
    <tr>
      <td>We have conducted <font color="blue"><font color="blue">clinical trial</font>s</font> of our drug <font color="blue">candidates</font> comparing our drug     <font color="blue">candidates</font> to both placebo and other <font color="blue">approved drugs</font></td>
    </tr>
    <tr>
      <td>For example, <font color="blue">regulatory</font> <font color="blue">authorities</font> may     not allow us to compare our drug <font color="blue">candidates</font> to placebo in a particular     <font color="blue">clinical indication</font> where <font color="blue">approved products</font> are available</td>
    </tr>
    <tr>
      <td>In that case,     both the cost and the amount of time required to conduct a <font color="blue">clinical trial</font>     <font color="blue">could increase</font></td>
    </tr>
    <tr>
      <td>The Drug Enforcement Administration, or DEA, limits the <font color="blue">availability</font> of the     <font color="blue">active ingredients</font> in certain of our current drug <font color="blue">candidates</font> and, as a     result, our quota may not be sufficient to complete <font color="blue"><font color="blue">clinical trial</font>s</font>, or to     <font color="blue">meet <font color="blue">commercial demand</font></font> or may result in <font color="blue">clinical delays</font></td>
    </tr>
    <tr>
      <td>The  DEA  <font color="blue">regulates chemical compounds as</font> Schedule I, II, III, IV or V     substances, with <font color="blue">Schedule I </font>substances considered to present the highest     risk of substance abuse and <font color="blue">Schedule V </font>substances the <font color="blue">lowest risk</font></td>
    </tr>
    <tr>
      <td><font color="blue">Certain     </font><font color="blue">active ingredients</font> in our current drug <font color="blue">candidates</font>, such as oxycodone, are     listed by the DEA as <font color="blue">Schedule II </font>under the <font color="blue">Controlled Substances Act </font>of     1970</td>
    </tr>
    <tr>
      <td>Consequently, their <font color="blue">manufacture</font>, research, shipment, storage, sale and     use are subject to a high degree of oversight and regulation</td>
    </tr>
    <tr>
      <td>For example,     all <font color="blue">Schedule II </font><font color="blue">drug <font color="blue">prescription</font>s must</font> be signed by a physician, physically     presented  to  a  <font color="blue">pharmacist</font>  and  may  not  be <font color="blue">refilled without</font> a new     <font color="blue">prescription</font></td>
    </tr>
    <tr>
      <td>Furthermore, the amount of <font color="blue">Schedule II </font>substances we can     obtain for <font color="blue"><font color="blue">clinical trial</font>s</font> and commercial <font color="blue">distribution</font> is limited by the DEA     and our quota may not be sufficient to complete <font color="blue"><font color="blue">clinical trial</font>s</font> or meet     <font color="blue">commercial demand</font></td>
    </tr>
    <tr>
      <td>There is a risk that DEA <font color="blue"><font color="blue">regulations</font> may interfere with</font>     the supply of the drugs used in our <font color="blue"><font color="blue">clinical trial</font>s</font>, and, in the future, our     ability to produce and distribute our products in the volume needed to meet     <font color="blue">commercial demand</font></td>
    </tr>
    <tr>
      <td><font color="blue">Government </font><font color="blue">agencies may establish</font> and <font color="blue">promulgate usage <font color="blue">guidelines</font></font> that     <font color="blue">directly apply</font> to our drug <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td><font color="blue">Government </font>agencies, professional and <font color="blue">medical societies</font>, and other groups     <font color="blue">may establish usage <font color="blue">guidelines</font></font> that apply to our drug <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td><font color="blue">These     </font><font color="blue">guidelines</font>  could  <font color="blue">address such matters as usage</font> and dose, among other     factors</td>
    </tr>
    <tr>
      <td><font color="blue">Application </font>of such <font color="blue">guidelines</font> could limit the use of our drug     <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>14     ______________________________________________________________________    [37]Table of <font color="blue">Contents       </font>Conducting <font color="blue"><font color="blue">clinical trial</font>s</font> of our drug <font color="blue">candidates</font> or <font color="blue">potential commercial</font>     sales of a <font color="blue">drug candidate</font> may expose us to <font color="blue">expensive <font color="blue">product <font color="blue">liability</font></font></font>     claims and we may not be able to maintain <font color="blue"><font color="blue">product <font color="blue">liability</font></font> insurance on</font>     <font color="blue">reasonable terms</font> or at all</td>
    </tr>
    <tr>
      <td>The risk of <font color="blue">product <font color="blue">liability</font></font> is inherent in the testing of <font color="blue">pharmaceutical</font>     products</td>
    </tr>
    <tr>
      <td>If  we <font color="blue">cannot <font color="blue">successfully</font></font> defend ourselves against product     <font color="blue">liability</font> claims, we may incur substantial <font color="blue">li<font color="blue">abilities</font></font> or be required to     limit or <font color="blue">terminate testing</font> of one or more of our products</td>
    </tr>
    <tr>
      <td>Our <font color="blue">inability</font> to     obtain sufficient <font color="blue">product <font color="blue">liability</font></font> insurance at an acceptable cost to     protect against potential <font color="blue">product <font color="blue">liability</font></font> claims <font color="blue">could prevent</font> or inhibit     the <font color="blue">commercialization</font> of our products</td>
    </tr>
    <tr>
      <td>We currently carry <font color="blue">clinical trial</font>     <font color="blue">insurance but</font> do not carry <font color="blue">product <font color="blue">liability</font></font> insurance</td>
    </tr>
    <tr>
      <td>If we <font color="blue">successfully</font>     <font color="blue">commercialize</font>  one or more of our drug <font color="blue">candidates</font>, we <font color="blue">may face product</font>     <font color="blue">liability</font> claims, <font color="blue">regardless</font> of FDA approval for <font color="blue">commercial <font color="blue">manufacturing</font></font>     and sale</td>
    </tr>
    <tr>
      <td>We may not be able to obtain <font color="blue">such insurance at</font> a <font color="blue">reasonable cost</font>,     if at all</td>
    </tr>
    <tr>
      <td>If our <font color="blue"><font color="blue">agreements</font> with</font> any <font color="blue">future corporate <font color="blue">collaborators</font> entitle</font>     us to indemnification against <font color="blue">product <font color="blue">liability</font></font> losses, such indemnification     may not be available or <font color="blue">adequate should</font> any claim arise</td>
    </tr>
    <tr>
      <td>If  we receive <font color="blue"><font color="blue">regulatory</font> approval</font> for our drug <font color="blue">candidates</font>, we and our     <font color="blue"><font color="blue">collaborators</font> will also</font> be subject to ongoing FDA <font color="blue">obligations</font> and continued     <font color="blue">regulatory</font> review, such as continued safety reporting <font color="blue">requirements</font>, and we     and our <font color="blue"><font color="blue">collaborators</font> may also</font> be subject to <font color="blue">additional</font> FDA post-marketing     <font color="blue">obligations</font> or <font color="blue">new <font color="blue">regulations</font></font>, all of which may result in <font color="blue">significant</font>     expense and limit our ability to <font color="blue">commercialize</font> our <font color="blue">potential drugs</font></td>
    </tr>
    <tr>
      <td>Any <font color="blue"><font color="blue">regulatory</font> approval</font>s that we receive for our drug <font color="blue">candidates</font> may also be     subject to <font color="blue">limitations</font> on the <font color="blue">indicated uses</font> for which the drug may be     marketed or contain <font color="blue">requirements</font> for <font color="blue">potentially</font> costly post-marketing     follow-up  studies</td>
    </tr>
    <tr>
      <td>In  addition, if the FDA approves any of our drug     <font color="blue">candidates</font>, the labeling, packaging, adverse event reporting, storage,     advertising, promotion and record keeping for the drug will be subject to     extensive <font color="blue">regulatory</font> <font color="blue">requirements</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">subsequent <font color="blue">discovery</font></font> of <font color="blue">previously</font>     <font color="blue">unknown problems with</font> the drug, including but not limited to <font color="blue">adverse events</font>     of <font color="blue">unanticipated severity</font> or frequency, or the <font color="blue">discovery</font> that <font color="blue">adverse events</font>     <font color="blue">previously</font> observed in <font color="blue">preclinical research</font> or <font color="blue"><font color="blue">clinical trial</font>s</font> that were     believed to be <font color="blue">minor actually constitute</font> much more serious problems, may     result in <font color="blue"><font color="blue">restrictions</font> on</font> the marketing of the drug, and could include     withdrawal of the drug from the market</td>
    </tr>
    <tr>
      <td>The FDA’s <font color="blue">policies may</font> change and <font color="blue">additional</font> <font color="blue">government</font> <font color="blue">regulations</font> may be     enacted  that  could  prevent or delay <font color="blue"><font color="blue">regulatory</font> approval</font> of our drug     <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot predict</font> the likelihood, nature or extent of adverse     <font color="blue">government</font>  regulation  that  may  arise  from  future  <font color="blue">legislation</font> or     <font color="blue">administrative action</font>, either in the <font color="blue">United States </font>or abroad</td>
    </tr>
    <tr>
      <td>If we are not     able  to  maintain  <font color="blue">regulatory</font> compliance, we may be subject to fines,     suspension or withdrawal of <font color="blue"><font color="blue">regulatory</font> approval</font>s, <font color="blue">product recalls</font>, seizure     of products, operating <font color="blue">restrictions</font> and <font color="blue">criminal prosecution</font></td>
    </tr>
    <tr>
      <td><font color="blue">Risks Relating </font>to our Collaboration Agreements          If King or other <font color="blue">outside <font color="blue">collaborators</font> fail</font> to <font color="blue">devote sufficient</font> time and     resources to our drug <font color="blue">development</font> programs, or if their performance is     substandard, our <font color="blue">regulatory</font> <font color="blue">submissions</font> and our <font color="blue">product <font color="blue">introductions</font> may</font> be     delayed</td>
    </tr>
    <tr>
      <td><font color="blue">Pursuant  </font>to  our <font color="blue">strategic alliance</font>, we will jointly manage <font color="blue">Phase III </font>    <font color="blue"><font color="blue">clinical trial</font>s</font> and NDA <font color="blue">submissions</font> in the <font color="blue">United States </font>for Remoxy and     other abuse resistant drug <font color="blue">candidates</font> with King</td>
    </tr>
    <tr>
      <td>We rely on King to devote     time and resources to the <font color="blue">development</font> and <font color="blue">commercialization</font> of Remoxy and     other  abuse  resistant drug <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>If King limits their time and     <font color="blue">resources attributable</font> to the <font color="blue">strategic alliance</font>, or <font color="blue">otherwise fails</font> to     perform as we expect, we may not achieve clinical and <font color="blue">regulatory</font> <font color="blue">milestones</font>     and <font color="blue">regulatory</font> <font color="blue">submissions</font> and related <font color="blue">product <font color="blue">introductions</font> may</font> be delayed     or prevented, and revenues that we would receive from these <font color="blue">activities will</font>     be less than expected</td>
    </tr>
    <tr>
      <td>15     ______________________________________________________________________    [38]Table of <font color="blue">Contents       </font>We  depend  on  in<font color="blue">dependent</font>  <font color="blue">investigators</font>  and <font color="blue">collaborators</font>, such as     <font color="blue">universities</font> and <font color="blue">medical institutions</font>, to conduct our <font color="blue"><font color="blue">clinical trial</font>s</font> under     <font color="blue"><font color="blue">agreements</font> with</font> us</td>
    </tr>
    <tr>
      <td>These <font color="blue">collaborators</font> are not our employees and we cannot     control the amount or timing of resources that they devote to our programs</td>
    </tr>
    <tr>
      <td>These <font color="blue">investigators</font> may not assign as great a priority to our programs or     <font color="blue">pursue them as diligently as</font> we would if we were undertaking <font color="blue">such programs</font>     ourselves</td>
    </tr>
    <tr>
      <td>If <font color="blue">outside <font color="blue">collaborators</font> fail</font> to <font color="blue">devote sufficient</font> time and     resources to our drug <font color="blue">development</font> programs, or if their performance is     substandard,  the  approval  of  our  <font color="blue">regulatory</font>  <font color="blue">submissions</font>  and our     <font color="blue">introductions</font> of <font color="blue">new drugs will</font> be delayed or prevented</td>
    </tr>
    <tr>
      <td>Our  <font color="blue">collaborators</font>  may  also have <font color="blue"><font color="blue">relationship</font>s with</font> other commercial     entities, some of <font color="blue">which may compete with us</font></td>
    </tr>
    <tr>
      <td>If outside <font color="blue">collaborators</font> assist     our <font color="blue"><font color="blue">competitor</font>s</font> to our detriment, the approval of our <font color="blue">regulatory</font> <font color="blue">submissions</font>     will be delayed and the <font color="blue">sales from</font> our products, if any are <font color="blue">commercialize</font>d,     will be less than expected</td>
    </tr>
    <tr>
      <td>If we fail to maintain our <font color="blue">strategic alliance</font> for Remoxy and other abuse     resistant  drugs,  we  may  have to reduce or delay our <font color="blue">drug candidate</font>     <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>Our plan for developing, <font color="blue">manufacturing</font> and <font color="blue">commercializing</font> Remoxy and other     <font color="blue">abuse <font color="blue">resistant drugs</font> currently</font> requires us to <font color="blue">successfully</font> maintain our     <font color="blue">strategic alliance</font> with King to advance our programs and provide funding to     support our <font color="blue">expenditure</font>s on Remoxy and other drug <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>If we are not     able to maintain our existing <font color="blue">strategic alliance</font> with King, we may have to     limit the size or scope of, or delay or abandon the <font color="blue">development</font> of <font color="blue">Remoxy     </font>and other abuse resistant drug <font color="blue">candidates</font> or undertake and fund <font color="blue">development</font>     of these drug <font color="blue">candidates</font> ourselves</td>
    </tr>
    <tr>
      <td>If we elect to fund drug <font color="blue">development</font>     <font color="blue">efforts with respect</font> to Remoxy and other abuse resistant drug <font color="blue">candidates</font> on     our  own,  we  may need to obtain <font color="blue">additional</font> capital, which may not be     <font color="blue">available on</font> acceptable terms, or at all</td>
    </tr>
    <tr>
      <td>We may not succeed at in-licensing drug <font color="blue">candidates</font> or <font color="blue">technologies</font> to expand     our <font color="blue">product pipeline</font></td>
    </tr>
    <tr>
      <td>We may not <font color="blue">successfully</font> in-license drug <font color="blue">candidates</font> or <font color="blue">technologies</font> to expand     our <font color="blue">product pipeline</font></td>
    </tr>
    <tr>
      <td>The number of such <font color="blue">candidates</font> or <font color="blue">technologies</font> is     limited</td>
    </tr>
    <tr>
      <td><font color="blue"><font color="blue">Competition </font>  </font>among   large  <font color="blue">pharmaceutical</font>  companies  and     bio<font color="blue">pharmaceutical</font> companies for promising drug <font color="blue">candidates</font> or <font color="blue">technologies</font> is     intense because such companies <font color="blue">generally</font> desire to expand their product     pipelines through in-licensing</td>
    </tr>
    <tr>
      <td>Our <font color="blue"><font color="blue">collaborative</font> <font color="blue">agreements</font> may</font> not succeed or <font color="blue">may give rise</font> to disputes     over <font color="blue">intellectual property</font> or other issues</td>
    </tr>
    <tr>
      <td>Our strategy to focus on <font color="blue">development</font> of novel drug <font color="blue">candidates</font> dis<font color="blue">covered by</font>     <font color="blue">third parties</font> requires us to <font color="blue">enter into</font> license <font color="blue"><font color="blue">agreements</font> with</font> such third     parties</td>
    </tr>
    <tr>
      <td>In  addition,  we <font color="blue">may <font color="blue">enter into</font> <font color="blue">collaborative</font> <font color="blue">agreements</font></font> to     <font color="blue">commercialize</font> our products, such as our <font color="blue">strategic alliance</font> with King</td>
    </tr>
    <tr>
      <td><font color="blue">Such     </font><font color="blue">agreements</font> are <font color="blue">generally</font> complex and <font color="blue">contain provisions</font> that <font color="blue">could give rise</font>     to <font color="blue">legal disputes</font>, including <font color="blue">potential disputes concerning ownership</font> of     <font color="blue">intellectual property</font> under <font color="blue">collaboration</font>s</td>
    </tr>
    <tr>
      <td>Such disputes can delay or     prevent the <font color="blue">development</font> of <font color="blue">potential new drug products</font>, or can lead to     lengthy, <font color="blue">expensive <font color="blue">litigation</font></font> or <font color="blue">arbitration</font></td>
    </tr>
    <tr>
      <td>Other factors relating to     <font color="blue">collaborative</font>  <font color="blue">agreements</font> may adversely affect the success of our drug     <font color="blue">candidates</font>, including:           •   the <font color="blue">development</font> of <font color="blue">parallel products by</font> our <font color="blue">collaborators</font> or by a     <font color="blue">competitor</font>;           •   <font color="blue">arrangements</font> with <font color="blue">collaborative</font> partners that limit or <font color="blue">preclude us</font>     from developing <font color="blue">certain products</font> or <font color="blue">technologies</font>;           •   <font color="blue">premature termination</font> of a <font color="blue">collaborative</font> agreement; or           •   <font color="blue">failure by</font> a <font color="blue">collaborative</font> partner to <font color="blue">devote sufficient</font> resources to     the <font color="blue">development</font> of our <font color="blue"><font color="blue">potential product</font>s</font></td>
    </tr>
    <tr>
      <td>16     ______________________________________________________________________    [39]Table of <font color="blue">Contents       </font><font color="blue">Risks Relating </font>to Commercialization          If physicians and patients do not accept and use our drugs, we will not     achieve sufficient <font color="blue">product revenues</font> and our business will suffer</td>
    </tr>
    <tr>
      <td>Even if the FDA approves our drugs, physicians and <font color="blue">patients may</font> not accept     and use them</td>
    </tr>
    <tr>
      <td><font color="blue">Acceptance </font>and use of our drugs will depend on a number of     factors including:           •   <font color="blue">perceptions</font> by members of the <font color="blue">healthcare community</font>, including     physicians, about the safety and <font color="blue">effective</font>ness of our drugs;           •   <font color="blue">published studies demonstrating</font> the cost-<font color="blue">effective</font>ness of our drugs     relative to <font color="blue">competing products</font>;           •   <font color="blue">availability</font> of <font color="blue">reimbursement</font> for our products from <font color="blue">government</font> or     <font color="blue">healthcare payers</font>;           •   our ability to implement a <font color="blue">risk <font color="blue">management</font></font> plan prior to the     <font color="blue">distribution</font> of any <font color="blue">Schedule II </font>drug; and           •   <font color="blue">effective</font>ness of marketing and <font color="blue">distribution</font> efforts by us and our     licensees and <font color="blue">distributors</font></td>
    </tr>
    <tr>
      <td><font color="blue">Because  </font>we expect to <font color="blue">rely on sales generated by</font> our <font color="blue">current lead drug</font>     <font color="blue">candidates</font> for <font color="blue">substantially</font> all of our revenues for the <font color="blue">foreseeable future</font>,     the failure of any of these drugs to <font color="blue">find <font color="blue">market acceptance</font> would harm</font> our     business and could require us to seek <font color="blue">additional</font> financing</td>
    </tr>
    <tr>
      <td>If  King  is  not successful in <font color="blue">commercializing</font> Remoxy and other abuse     <font color="blue">resistant drugs</font>, our revenues and our business will suffer</td>
    </tr>
    <tr>
      <td>Our ability to <font color="blue">commercialize</font> Remoxy and other abuse <font color="blue">resistant drugs</font> and     <font color="blue">generate royalties from product sales</font> of such drugs will depend on King’s     <font color="blue">abilities</font>  in <font color="blue">assisting us</font> in developing such drugs and in maintaining     <font color="blue"><font color="blue">regulatory</font> approval</font> and achieving <font color="blue">market acceptance</font> of <font color="blue">such drugs once</font>     <font color="blue">commercialize</font>d</td>
    </tr>
    <tr>
      <td>King may elect to in<font color="blue">dependent</font>ly develop drugs that could     <font color="blue">compete with ours</font> or fail to <font color="blue">commit sufficient resources</font> to the <font color="blue">development</font>,     marketing  and  <font color="blue">distribution</font> of Remoxy and other abuse <font color="blue">resistant drugs</font>     developed  under our <font color="blue">strategic alliance</font></td>
    </tr>
    <tr>
      <td>King may not <font color="blue">proceed with</font> the     <font color="blue">commercialization</font> of Remoxy and other abuse <font color="blue">resistant drugs</font> developed under     our <font color="blue">strategic alliance</font> with the same degree of <font color="blue">urgency as</font> we would because     of other priorities they face</td>
    </tr>
    <tr>
      <td>If King is not successful in <font color="blue">commercializing</font>     Remoxy for a variety of reasons, including but not limited to <font color="blue">competition</font>     from other <font color="blue">pharmaceutical</font> companies, or if King fails to perform as we     expect, our potential for <font color="blue">revenue from drugs</font> developed in <font color="blue">connection with</font>     our <font color="blue">strategic alliance</font> with King, if any, could be <font color="blue">dramatically reduced</font> and     our business <font color="blue">would suffer</font></td>
    </tr>
    <tr>
      <td>If  we are unable to develop our own sales, marketing and <font color="blue">distribution</font>     cap<font color="blue">abilities</font>, or if we are not successful in contracting with <font color="blue">third parties</font>     for these <font color="blue">services on</font> favorable terms, or at all, our <font color="blue">product revenues</font> could     be <font color="blue">disappointing</font></td>
    </tr>
    <tr>
      <td>We currently have no sales, marketing or <font color="blue">distribution</font> cap<font color="blue">abilities</font></td>
    </tr>
    <tr>
      <td><font color="blue">Except     </font>with regard to products developed under our <font color="blue">strategic alliance</font> with King, in     order to <font color="blue">commercialize</font> our products, if any are approved by the FDA, we will     either have to develop such cap<font color="blue">abilities</font> internally or <font color="blue">collaborate with</font>     third  parties  who can perform these services for us</td>
    </tr>
    <tr>
      <td>If we decide to     <font color="blue">commercialize</font> any of our <font color="blue">drugs ourselves</font>, we may not be able to hire the     <font color="blue">necessary</font> experienced personnel and build sales, marketing and <font color="blue">distribution</font>     <font color="blue">operations</font>  which  are capable of <font color="blue">successfully</font> launching new drugs and     generating sufficient <font color="blue">product revenues</font></td>
    </tr>
    <tr>
      <td>In addition, establishing such     <font color="blue">operations</font> will take time and involve <font color="blue">significant</font> expense</td>
    </tr>
    <tr>
      <td>If we decide to <font color="blue">enter into</font> new co-promotion or other licensing <font color="blue">arrangements</font>     with <font color="blue">third parties</font>, we may be unable to locate acceptable <font color="blue">collaborators</font>     because the number of potential <font color="blue">collaborators</font> is limited and because of     <font color="blue">competition</font> from others for similar alliances with potential <font color="blue">collaborators</font></td>
    </tr>
    <tr>
      <td>Even if we are able to identify one or more acceptable new <font color="blue">collaborators</font>, we     may not be able to <font color="blue">enter into</font> any <font color="blue">collaborative</font> <font color="blue">arrangements</font> on favorable     terms, or at all</td>
    </tr>
    <tr>
      <td>17     ______________________________________________________________________    [40]Table of <font color="blue">Contents       </font>In addition, due to the nature of the market for <font color="blue">pain <font color="blue">management</font> products</font>,     it may be <font color="blue">necessary</font> for us to license all or <font color="blue">substantially</font> all of our drug     <font color="blue">candidates</font> not <font color="blue">covered by</font> our <font color="blue">strategic alliance</font> with King to a single     collaborator, thereby eliminating our <font color="blue">opportunity</font> to <font color="blue">commercialize</font> these     other <font color="blue">pain <font color="blue">management</font> products</font> in<font color="blue">dependent</font>ly</td>
    </tr>
    <tr>
      <td>If we <font color="blue">enter into</font> any such new     <font color="blue">collaborative</font> <font color="blue">arrangements</font>, our revenues are likely to be lower than if we     marketed and sold our <font color="blue">products ourselves</font></td>
    </tr>
    <tr>
      <td>In addition, any revenues we receive <font color="blue">would depend upon</font> our <font color="blue">collaborators</font>’     <font color="blue">efforts which may</font> not be <font color="blue">adequate due</font> to lack of attention or resource     <font color="blue">commitments</font>,  <font color="blue">management</font>  turnover, change of strategic focus, further     business <font color="blue">combinations</font> or other <font color="blue">factors outside</font> of our control</td>
    </tr>
    <tr>
      <td><font color="blue">Depending     </font>upon  the  terms of our <font color="blue">collaboration</font>, the remedies we have against an     under-performing collaborator may be limited</td>
    </tr>
    <tr>
      <td>If we were to terminate the     <font color="blue">relationship</font>,  it may be <font color="blue">difficult</font> or impossible to find a <font color="blue">replacement</font>     <font color="blue">collaborator on</font> acceptable terms, or at all</td>
    </tr>
    <tr>
      <td>If  we cannot compete <font color="blue">successfully</font> for market share against other drug     companies, we may not achieve sufficient <font color="blue">product revenues</font> and our business     will suffer</td>
    </tr>
    <tr>
      <td>The market for our drug <font color="blue">candidates</font> is characterized by intense <font color="blue">competition</font>     and  rapid  <font color="blue">technological advances</font></td>
    </tr>
    <tr>
      <td>If our drug <font color="blue">candidates</font> receive FDA     approval, they <font color="blue"><font color="blue">will compete</font> with</font> a number of existing and <font color="blue">future drugs</font> and     therapies developed, <font color="blue">manufacture</font>d and <font color="blue">marketed by others</font></td>
    </tr>
    <tr>
      <td>Existing or future     <font color="blue">competing products</font> may provide greater <font color="blue">therapeutic</font> convenience or clinical     or other benefits for a <font color="blue">specific indication than</font> our products, or may offer     comparable  <font color="blue">performance at</font> a <font color="blue">lower cost</font></td>
    </tr>
    <tr>
      <td>If our products are unable to     capture and maintain market share, we may not achieve <font color="blue">sufficient product</font>     revenues and our business will suffer</td>
    </tr>
    <tr>
      <td>We <font color="blue">will compete</font> for market share against fully integrated <font color="blue">pharmaceutical</font>     companies  or  other  companies  that  are  <font color="blue">collaborating</font>  with larger     <font color="blue">pharmaceutical</font> companies, academic institutions, <font color="blue">government</font> agencies and     other public and <font color="blue">private research <font color="blue">organizations</font></font></td>
    </tr>
    <tr>
      <td>Many of these <font color="blue"><font color="blue">competitor</font>s</font>     have opioid <font color="blue">painkillers</font> already approved or in <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>In addition,     many of these <font color="blue"><font color="blue">competitor</font>s</font>, either alone or <font color="blue">together with</font> their <font color="blue">collaborative</font>     partners,  operate  larger  research and <font color="blue">development</font> programs and have     <font color="blue">substantially</font>  greater  financial  resources  than  we  do, as well as     <font color="blue">significant</font>ly greater experience in:           •   developing drugs;           •   <font color="blue">conducting pre<font color="blue">clinical testing</font></font> and human <font color="blue"><font color="blue">clinical trial</font>s</font>;           •   obtaining FDA and other <font color="blue"><font color="blue">regulatory</font> approval</font>s of drugs;           •   <font color="blue">formulating</font> and <font color="blue">manufacturing</font> drugs; and           •   launching, marketing, distributing and <font color="blue">selling drugs</font></td>
    </tr>
    <tr>
      <td>Our ability to generate <font color="blue">product revenues</font> will be diminished if we fail to     obtain acceptable prices or an <font color="blue">adequate level</font> of <font color="blue">reimbursement</font> for our     products from <font color="blue">healthcare payers</font></td>
    </tr>
    <tr>
      <td>Our ability to <font color="blue">commercialize</font> our drugs, alone or with <font color="blue">collaborators</font>, will     depend in part on the extent to which <font color="blue">reimbursement</font> will be <font color="blue">available from</font>:           •   <font color="blue">government</font> and health administration <font color="blue">authorities</font>;           •   <font color="blue">private health <font color="blue">maintenance <font color="blue">organizations</font></font></font> and <font color="blue">health insurers</font>; and           •   other <font color="blue">healthcare payers</font></td>
    </tr>
    <tr>
      <td><font color="blue">Significant </font><font color="blue">uncertainty</font> exists as to the <font color="blue">reimbursement</font> status of newly     <font color="blue">approved healthcare products</font></td>
    </tr>
    <tr>
      <td><font color="blue">Healthcare </font>payers, including Medicare, health     <font color="blue">maintenance <font color="blue">organizations</font></font> and <font color="blue">managed care <font color="blue">organizations</font></font>, are <font color="blue">challenging</font>     the <font color="blue">prices charged</font> for <font color="blue">medical products</font> and services and/or are seeking     <font color="blue">pharmacoeconomic data</font> to <font color="blue">justify formulary acceptance</font> and <font color="blue">reimbursement</font>     practices</td>
    </tr>
    <tr>
      <td>We currently have not <font color="blue">generated pharmacoeconomic</font>                                           18     ______________________________________________________________________    [41]Table of <font color="blue">Contents       </font>data  on  any  of our products</td>
    </tr>
    <tr>
      <td><font color="blue">Government </font>and other <font color="blue">healthcare payers</font>     increasingly are attempting to <font color="blue">contain healthcare costs by limiting both</font>     coverage and the level of <font color="blue">reimbursement</font> for drugs, and by refusing, in some     cases,  to  <font color="blue">provide coverage</font> for uses of <font color="blue">approved products</font> for disease     <font color="blue">indications</font> for which the FDA has or has not <font color="blue">granted labeling approval</font></td>
    </tr>
    <tr>
      <td><font color="blue">Adequate </font>third-party insurance coverage may not be available to patients for     any  products we discover and develop, alone or with <font color="blue">collaborators</font></td>
    </tr>
    <tr>
      <td>If     <font color="blue">government</font> and other <font color="blue">healthcare payers</font> do not <font color="blue">provide adequate coverage</font> and     <font color="blue">reimbursement</font> levels for our products, <font color="blue">market acceptance</font> of our product     <font color="blue">candidates</font> could be limited</td>
    </tr>
    <tr>
      <td><font color="blue">Risks Relating </font>to our Intellectual Property          If we are unable to protect our <font color="blue">intellectual property</font> our <font color="blue"><font color="blue">competitor</font>s</font> could     develop and <font color="blue">market products with</font> similar features that <font color="blue">may reduce demand</font> for     our products</td>
    </tr>
    <tr>
      <td>Our success, <font color="blue">competitive position</font> and <font color="blue">potential <font color="blue">future revenues</font> will depend</font>     in part on our ability to protect our <font color="blue">intellectual property</font></td>
    </tr>
    <tr>
      <td>If we, Albert     Einstein  College of Medicine or our other <font color="blue">collaborators</font> fail to file,     prosecute or maintain certain patents, our <font color="blue"><font color="blue">competitor</font>s</font> could market products     that  contain  features  and clinical benefits similar to those of our     products, and demand for our <font color="blue">products could</font> decline as a result</td>
    </tr>
    <tr>
      <td>We may be involved in <font color="blue">additional</font> challenges to our <font color="blue">intellectual property</font></td>
    </tr>
    <tr>
      <td>An     <font color="blue">adverse outcome</font> of a challenge to our <font color="blue">intellectual property</font> could result in     loss of claims of patents or other <font color="blue">intellectual property</font> rights that pertain     to  <font color="blue">certain drugs</font> we currently have under <font color="blue">development</font> and could have a     material <font color="blue">adverse <font color="blue">impact on</font></font> our <font color="blue">future revenues</font></td>
    </tr>
    <tr>
      <td>We intend to file <font color="blue">additional</font> patent <font color="blue">application</font>s relating to our <font color="blue">technology</font>,     products and processes</td>
    </tr>
    <tr>
      <td>We may direct <font color="blue">Albert Einstein College of Medicine </font>or     our <font color="blue">collaborators</font> to file <font color="blue">additional</font> patent <font color="blue">application</font>s relating to the     licensed <font color="blue">technology</font> or we may do so ourselves</td>
    </tr>
    <tr>
      <td>However, our <font color="blue"><font color="blue">competitor</font>s</font> may     challenge, invalidate or <font color="blue">circumvent</font> any of our current or <font color="blue">future patents</font></td>
    </tr>
    <tr>
      <td>These  <font color="blue">patents may also fail</font> to <font color="blue">provide us with meaningful competitive</font>     <font color="blue">advantages</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">may become involved</font> in <font color="blue">expensive <font color="blue">litigation</font></font> or other <font color="blue">legal proceedings</font>     related to our existing <font color="blue">intellectual property</font> rights, including patents</td>
    </tr>
    <tr>
      <td>We  expect  that  we  will rely upon patents, <font color="blue">trade secrets</font>, know-how,     <font color="blue">continuing <font color="blue">technological innovations</font></font> and licensing <font color="blue">opportunities</font> to develop     and maintain our <font color="blue">competitive position</font></td>
    </tr>
    <tr>
      <td>Others may in<font color="blue">dependent</font>ly develop     <font color="blue">substantially</font> equivalent proprietary information or be <font color="blue">issued patents</font> that     <font color="blue">may prevent</font> the sale of our products or know-how or require us to license     such information and pay <font color="blue">significant</font> fees or royalties in order to produce     our products</td>
    </tr>
    <tr>
      <td>Our <font color="blue">technology</font> could infringe upon claims of patents owned by others</td>
    </tr>
    <tr>
      <td>If we     were found to be <font color="blue">infringing on</font> a patent held by another, we might have to     seek a license to use the patented <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>In that case, we might not be     able to obtain such a <font color="blue">license on terms</font> acceptable to us, or at all</td>
    </tr>
    <tr>
      <td>If a     legal action were to be brought against us or our <font color="blue">licensors</font>, we could incur     substantial defense costs, and any <font color="blue">such action might</font> not be resolved in our     favor</td>
    </tr>
    <tr>
      <td>If such a dispute were to be <font color="blue">resolved against us</font>, we could have to     pay the other party large sums of money and our use of our <font color="blue">technology</font> and     the testing, <font color="blue">manufacture</font>, marketing or sale of one or more of our proposed     <font color="blue">products could</font> be restricted or prohibited</td>
    </tr>
    <tr>
      <td>19     ______________________________________________________________________    [42]Table of <font color="blue">Contents       </font><font color="blue">Risks Relating </font>to our Business and Strategy          <font color="blue">Competition </font> for <font color="blue">qualified personnel</font> in the <font color="blue">pharmaceutical</font> industry is     intense, and if we are not successful in attracting and retaining qualified     personnel, we could experience delays in completing <font color="blue">necessary</font> clinical     trials, in the <font color="blue"><font color="blue">regulatory</font> approval</font> process or in <font color="blue">formulating</font>, <font color="blue">manufacturing</font>,     marketing and selling our <font color="blue"><font color="blue">potential product</font>s</font></td>
    </tr>
    <tr>
      <td>We  will need to hire <font color="blue">additional</font> <font color="blue">qualified personnel</font> with expertise in     clinical research, pre<font color="blue">clinical testing</font>, <font color="blue">government</font> regulation, <font color="blue">formulation</font>     and  <font color="blue">manufacturing</font>  and  sales and marketing</td>
    </tr>
    <tr>
      <td>We compete for qualified     individuals with numerous bio<font color="blue">pharmaceutical</font> companies, <font color="blue">universities</font> and     other <font color="blue">research institutions</font></td>
    </tr>
    <tr>
      <td><font color="blue">Competition </font>for such individuals, <font color="blue">particularly</font>     <font color="blue">in the San Francisco Bay </font>area, is intense, and our search for <font color="blue">such personnel</font>     may not be successful</td>
    </tr>
    <tr>
      <td><font color="blue">Attracting </font>and retaining <font color="blue">qualified personnel</font> will be     critical to our success</td>
    </tr>
    <tr>
      <td>If  third-party  <font color="blue">manufacture</font>rs  of  our drug <font color="blue">candidates</font> fail to devote     sufficient time and resources to our concerns, or if their performance is     substandard, our <font color="blue"><font color="blue">clinical trial</font>s</font> and <font color="blue">product <font color="blue">introductions</font> may</font> be delayed     and our costs may be <font color="blue">higher than</font> expected</td>
    </tr>
    <tr>
      <td>We have no <font color="blue">manufacturing</font> <font color="blue">facilities</font> and have limited experience in drug     product <font color="blue">development</font> and <font color="blue">commercial <font color="blue">manufacturing</font></font></td>
    </tr>
    <tr>
      <td>We lack the resources and     expertise to formulate, <font color="blue">manufacture</font> or test the <font color="blue">technical performance</font> of our     drug  <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">currently rely on</font> a limited number of experienced     personnel and a small number of contract <font color="blue">manufacture</font>rs and other vendors to     formulate, test, supply, store and <font color="blue">distribute drug supplies</font> for our clinical     trials</td>
    </tr>
    <tr>
      <td>Our <font color="blue">reliance on</font> a limited number of <font color="blue">vendors exposes us</font> to the     following  risks,  any  of <font color="blue">which could delay</font> our <font color="blue"><font color="blue">clinical trial</font>s</font>, and,     <font color="blue">consequently</font>, FDA approval of our drug <font color="blue">candidates</font> and <font color="blue">commercialization</font> of     our products, result in <font color="blue">higher costs</font>, or <font color="blue">deprive us</font> of <font color="blue">potential product</font>     revenues:           •   Contract commercial <font color="blue">manufacture</font>rs, their sub-contractors or other     <font color="blue">third parties</font> we rely on, may encounter <font color="blue">difficult</font>ies in achieving the volume     of production needed to <font color="blue">satisfy clinical</font> needs or <font color="blue">commercial demand</font>, may     experience <font color="blue">technical issues</font> that <font color="blue">impact quality</font> or <font color="blue">compliance with</font>     applicable and <font color="blue">strictly enforced <font color="blue">regulations</font> governing</font> the <font color="blue">manufacture</font> of     <font color="blue">pharmaceutical</font> products, and may experience shortages of <font color="blue">qualified personnel</font>     to adequately staff production <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>•   Our contract <font color="blue">manufacture</font>rs could default on their <font color="blue"><font color="blue">agreements</font> with</font> us     to <font color="blue">provide <font color="blue">clinical supplies</font></font> or meet our <font color="blue">requirements</font> for <font color="blue">commercialization</font>     of our products</td>
    </tr>
    <tr>
      <td>•   The use of alternate <font color="blue">manufacture</font>rs may be <font color="blue">difficult</font> because the number     of potential <font color="blue">manufacture</font>rs that have the <font color="blue">necessary</font> <font color="blue">government</font>al licenses to     produce <font color="blue">narcotic products</font> is limited</td>
    </tr>
    <tr>
      <td>Additionally, the FDA and the DEA must     approve any alternative <font color="blue">manufacture</font>r of our products before we may use the     alternative <font color="blue">manufacture</font>r to produce our supplies</td>
    </tr>
    <tr>
      <td>•   It may be <font color="blue">difficult</font> or impossible for us to find a <font color="blue">replacement</font>     <font color="blue">manufacture</font>r on acceptable <font color="blue">terms quickly</font>, or at all</td>
    </tr>
    <tr>
      <td>Our contract     <font color="blue">manufacture</font>rs and <font color="blue">vendors may</font> not perform as agreed or may not remain in the     contract <font color="blue">manufacturing</font> business for the time required to <font color="blue">successfully</font>     produce, store and distribute our products</td>
    </tr>
    <tr>
      <td>•   If any contract <font color="blue">manufacture</font>r makes <font color="blue">improvements</font> in the <font color="blue">manufacturing</font>     process for our products, we may not own, or may have to share, the     <font color="blue">intellectual property</font> rights to <font color="blue">such innovation</font></td>
    </tr>
    <tr>
      <td>Our employees and <font color="blue">consultants</font> are <font color="blue">generally</font> subject to <font color="blue"><font color="blue">confidential</font>ity</font> or     other <font color="blue"><font color="blue">agreements</font> with</font> their <font color="blue">former employers</font> and they <font color="blue">may <font color="blue">inadvertently</font></font> or     <font color="blue">otherwise violate</font> those <font color="blue">agreements</font></td>
    </tr>
    <tr>
      <td>Many  of  our  employees  and  <font color="blue">consultants</font> were <font color="blue">previously</font> employed at     <font color="blue">universities</font> or bio<font color="blue">technology</font> or <font color="blue">pharmaceutical</font> companies</td>
    </tr>
    <tr>
      <td>While we require     our employees and <font color="blue">consultants</font> to honor any <font color="blue">agreements</font> they may have entered     into  prior  to  working  with us, we may be subject to claims that we     <font color="blue">inadvertently</font>  or  otherwise  used or disclosed <font color="blue">trade secrets</font> or other     <font color="blue">confidential</font> information belonging to <font color="blue">former employers</font></td>
    </tr>
    <tr>
      <td>Failure to defend     such claims could result in loss of valuable rights or personnel, which in     turn could harm or prevent <font color="blue">commercialization</font>                                           20     ______________________________________________________________________    [43]Table of <font color="blue">Contents       </font>of  our drug <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td><font color="blue">Successful </font><font color="blue">defense against such</font> claims can be     expensive and <font color="blue">might distract us from</font> executing our strategies</td>
    </tr>
    <tr>
      <td>Law <font color="blue">enforcement concerns over diversion</font> of opioids and <font color="blue">social issues around</font>     abuse of <font color="blue">opioids may</font> make the <font color="blue"><font color="blue">regulatory</font> approval</font> process very <font color="blue">difficult</font> for     our drug <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>Law <font color="blue">enforcement agencies</font> or <font color="blue">regulatory</font> agencies     <font color="blue">may apply policies</font> that seek to limit the <font color="blue">availability</font> of opioids</td>
    </tr>
    <tr>
      <td><font color="blue">Such     </font><font color="blue">efforts may adversely affect</font> the <font color="blue"><font color="blue">regulatory</font> approval</font> process for our drug     <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td><font color="blue">Developments </font>by <font color="blue"><font color="blue">competitor</font>s</font> may render our products or <font color="blue">technologies</font> obsolete     or non-competitive</td>
    </tr>
    <tr>
      <td><font color="blue">Alternative </font><font color="blue">technologies</font> and products are being developed to improve or     replace the use of opioids for pain <font color="blue">management</font>, several of which are in     <font color="blue"><font color="blue">clinical trial</font>s</font> or are <font color="blue">awaiting approval from</font> the FDA In addition, the     <font color="blue">active ingredients</font> in nearly all <font color="blue">opioid drugs</font> are available in generic form</td>
    </tr>
    <tr>
      <td>Drug  companies  that  sell generic <font color="blue">opioid drugs</font> represent substantial     <font color="blue">competition</font></td>
    </tr>
    <tr>
      <td>Many  of  these  <font color="blue">organizations</font>  competing  with  us have     <font color="blue">substantially</font> greater capital resources, larger research and <font color="blue">development</font>     staffs  and  <font color="blue">facilities</font>, greater experience in drug <font color="blue">development</font> and in     obtaining <font color="blue"><font color="blue">regulatory</font> approval</font>s and greater <font color="blue">manufacturing</font> and marketing     cap<font color="blue">abilities</font> than we do</td>
    </tr>
    <tr>
      <td>Our <font color="blue"><font color="blue">competitor</font>s</font> may market less expensive or more     <font color="blue">effective</font> drugs that <font color="blue">would compete with</font> our product <font color="blue">candidates</font> or reach     <font color="blue">market with competing drugs</font> before we are able to <font color="blue">reach market with</font> our drug     <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">organizations</font> also compete with us to <font color="blue">attract qualified</font>     personnel  and  partners  for  <font color="blue"><font color="blue">acquisition</font>s</font>,  joint  ventures or other     <font color="blue">collaboration</font>s</td>
    </tr>
    <tr>
      <td>Business <font color="blue"><font color="blue">interruption</font>s could limit</font> our ability to operate our business</td>
    </tr>
    <tr>
      <td>Our <font color="blue">operations</font> as well as those of our <font color="blue">collaborators</font> on which we depend are     vulnerable to damage or <font color="blue">interruption</font> from computer viruses, human error,     natural disasters, electrical and telecommunication failures, international     acts of terror and similar events</td>
    </tr>
    <tr>
      <td>We have not established a formal disaster     recovery plan and our back-up <font color="blue">operations</font> and our business <font color="blue">interruption</font>     <font color="blue">insurance may</font> not be adequate to <font color="blue">compensate us</font> for losses we may suffer</td>
    </tr>
    <tr>
      <td>A     <font color="blue">significant</font> business <font color="blue">interruption</font> could result in losses or <font color="blue">damages incurred</font>     by us and require us to cease or curtail our <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td><font color="blue">Risks Relating </font>to Manufacturing          We rely on third-party commercial drug <font color="blue">manufacture</font>rs for <font color="blue">drug supply</font></td>
    </tr>
    <tr>
      <td>Approved third-party commercial drug <font color="blue">manufacture</font>rs may subsequently be     <font color="blue">stopped from</font> producing, storing, shipping or testing our <font color="blue">drug products due</font>     to their non-<font color="blue">compliance with</font> federal, state or <font color="blue">local <font color="blue">regulations</font></font></td>
    </tr>
    <tr>
      <td><font color="blue">Drug     </font><font color="blue">manufacture</font>rs are subject to <font color="blue">ongoing periodic unannounced inspection by</font> the     FDA, the DEA, and <font color="blue">corresponding</font> state and foreign <font color="blue">government</font> agencies to     ensure  strict  compliance  with good <font color="blue">manufacturing</font> practice and other     <font color="blue">government</font> <font color="blue">regulations</font> and <font color="blue">corresponding</font> foreign standards</td>
    </tr>
    <tr>
      <td>We do not have     control over third-party <font color="blue">manufacture</font>rs’ <font color="blue">compliance with</font> these <font color="blue">regulations</font>     and standards</td>
    </tr>
    <tr>
      <td>In  addition, even if we <font color="blue">enter into</font> long-term supply <font color="blue">arrangements</font> with     third-party suppliers, we <font color="blue">cannot control</font> changes in strategy by third-party     suppliers that affect their ability or <font color="blue">willingness</font> to continue to supply our     <font color="blue">drug products on</font> acceptable terms</td>
    </tr>
    <tr>
      <td>If our <font color="blue">drug supply</font> for one of our drug <font color="blue">candidates</font> was <font color="blue">interrupted</font>, our     <font color="blue">operations</font> could be <font color="blue">negatively affected</font></td>
    </tr>
    <tr>
      <td>21     ______________________________________________________________________    [44]Table of <font color="blue">Contents       </font>If we <font color="blue">cannot formulate</font> and scale-up a wide range of <font color="blue">dosage forms</font> of <font color="blue">Remoxy     </font>and other abuse resistant product <font color="blue">candidates</font>, we and King might determine     that the commercial <font color="blue">opportunity</font> for Remoxy is too limited to <font color="blue">warrant further</font>     <font color="blue">investment</font> in <font color="blue">clinical testing</font> and <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>We plan to formulate and scale-up a wide range of <font color="blue">dosage forms</font> of Remoxy and     other abuse resistant drug <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>We may not be able to <font color="blue">successfully</font>     complete our <font color="blue">formulation</font> or scale-up activities or we may determine that the     commercial <font color="blue">opportunity</font> for Remoxy and other abuse resistant drug <font color="blue">candidates</font>     in certain <font color="blue">dosage forms</font> is too limited to <font color="blue">warrant further</font> <font color="blue">investment</font></td>
    </tr>
    <tr>
      <td>If we     are <font color="blue">unsuccessful</font> in our <font color="blue">formulation</font> or scale-up activities with Remoxy and     other abuse resistant drug <font color="blue">candidates</font>, our future revenue from <font color="blue">milestones</font>     and  royalties under our <font color="blue">strategic alliance</font> with King may be less than     expected and our <font color="blue">operations</font> may suffer</td>
    </tr>
    <tr>
      <td>We rely on Durect, our <font color="blue">sole source provider</font> of <font color="blue">certain <font color="blue">components</font></font> of <font color="blue">Remoxy     </font>and other abuse resistant drug <font color="blue">candidates</font>, to produce Remoxy and other abuse     resistant drug <font color="blue">candidates</font> for <font color="blue">clinical supplies</font> and <font color="blue">will rely on</font> Durect to     produce commercial supplies of these <font color="blue">components</font></td>
    </tr>
    <tr>
      <td>We rely on Durect as our <font color="blue">sole source provider</font> of <font color="blue">certain <font color="blue">components</font></font> of     Remoxy and other abuse resistant drug <font color="blue">candidates</font>, and <font color="blue">will rely solely on</font>     Durect to produce commercial supplies of these <font color="blue">components</font></td>
    </tr>
    <tr>
      <td>Durect’s failure     to achieve and maintain satisfactory <font color="blue">manufacturing</font> standards could result in     <font color="blue">product recalls</font> or withdrawals, delays or failures in <font color="blue">product testing</font> or     delivery, cost overruns or other problems that <font color="blue">could materially harm</font> our     business</td>
    </tr>
    <tr>
      <td>Durect  may  encounter <font color="blue">manufacturing</font> <font color="blue">difficult</font>ies involving     production yields, quality control and <font color="blue">quality assurance</font></td>
    </tr>
    <tr>
      <td>Durect is subject     to <font color="blue">ongoing periodic unannounced inspection by</font> the FDA and <font color="blue">corresponding</font>     state and foreign agencies to ensure strict <font color="blue">compliance with</font> cGMP and other     <font color="blue">government</font>  <font color="blue">regulations</font> and <font color="blue">corresponding</font> foreign standards</td>
    </tr>
    <tr>
      <td>We cannot     control Durect’s <font color="blue">compliance with</font> these <font color="blue">regulations</font> and standards</td>
    </tr>
    <tr>
      <td>To  date,  Durect  has  not  produced commercial-scale supply of these     <font color="blue">components</font></td>
    </tr>
    <tr>
      <td>If we and King receive <font color="blue">marketing approval</font> for and <font color="blue">commercially</font>     launch Remoxy or other abuse resistant <font color="blue">candidates</font>, we anticipate that <font color="blue">Durect     </font>will need to expand its <font color="blue">manufacturing</font> capacity, possibly materially</td>
    </tr>
    <tr>
      <td><font color="blue">Durect     </font>may not be able to increase its <font color="blue">manufacturing</font> capacity for Remoxy and other     abuse resistant drug <font color="blue">candidates</font> in a timely or <font color="blue">economic manner</font>, or at all</td>
    </tr>
    <tr>
      <td>Moreover, <font color="blue">significant</font> scale up of <font color="blue">manufacturing</font> may require <font color="blue">additional</font>     validation studies, which the FDA must review and approve</td>
    </tr>
    <tr>
      <td>If Durect is     unable  to  <font color="blue">successfully</font>  increase the <font color="blue">manufacturing</font> capacity for such     <font color="blue">components</font> of Remoxy and other abuse <font color="blue">resistant drugs</font>, at an acceptable cost     or otherwise, and we are unable to establish alternative <font color="blue">manufacturing</font>     cap<font color="blue">abilities</font>, the <font color="blue">commercial launch</font> or continued <font color="blue">commercialization</font> after a     <font color="blue">commercial launch</font> of Remoxy and other abuse <font color="blue">resistant drugs</font> may be delayed,     prevented or impaired or there may be a shortage in supply, <font color="blue">which would</font> harm     our revenues and cause our business to suffer</td>
    </tr>
    <tr>
      <td><font color="blue">Risks Relating </font>to an Investment in our Common Stock          Our stock price has <font color="blue">been volatile</font> and could experience a <font color="blue">sudden decline</font> in     value</td>
    </tr>
    <tr>
      <td>Our <font color="blue">common stock</font> has experienced <font color="blue">significant</font> price and <font color="blue">volume <font color="blue">fluctuations</font></font>     and <font color="blue">may continue</font> to experience <font color="blue">volatility</font> in the future</td>
    </tr>
    <tr>
      <td>You may not be able     to sell your <font color="blue">shares quickly</font> or at the <font color="blue">latest <font color="blue">market price</font></font> if trading in our     stock is not active or the volume is low</td>
    </tr>
    <tr>
      <td>The <font color="blue">following factors</font>, in addition     to other <font color="blue">risk factors described</font> in this section, may have a <font color="blue">significant</font>     <font color="blue">impact on</font> the <font color="blue">market price</font> of our <font color="blue">common stock</font>:           •   the success of our <font color="blue">collaboration</font> <font color="blue">agreements</font>;           •   results of or delays in our preclinical and <font color="blue"><font color="blue">clinical trial</font>s</font>;           •   publicity regarding actual or <font color="blue">potential medical</font> results relating to     products under <font color="blue">development</font> by us or others;           •   <font color="blue">announcements</font> of <font color="blue">technological innovations</font> or <font color="blue">new commercial products</font>     by us or others;           •   <font color="blue">development</font>s in patent or other <font color="blue">proprietary rights by us</font> or others;                                           22     ______________________________________________________________________    [45]Table of <font color="blue">Contents       </font>  •   comments or <font color="blue">opinions by securities analysts</font> or <font color="blue">major <font color="blue">stockholders</font></font>;           •   <font color="blue">future sales</font> of our <font color="blue">common stock</font> by <font color="blue">existing <font color="blue">stockholders</font></font>;           •   <font color="blue">regulatory</font> <font color="blue">development</font>s or changes in <font color="blue">regulatory</font> guidance;           •   <font color="blue">litigation</font> or threats of <font color="blue">litigation</font>;           •   economic and other <font color="blue">external factors</font> or other disaster or crises;           •   the <font color="blue">departure</font> of any of our officers, <font color="blue">directors</font> or <font color="blue">key employees</font>;           •   period-to-period <font color="blue">fluctuations</font> in financial results; and           •   limited <font color="blue">daily trading volume</font></td>
    </tr>
    <tr>
      <td>The National Association of Securities Dealers, Inc, or NASD, and the     Securities and Exchange Commission, or SEC, have <font color="blue">adopted certain new rules</font></td>
    </tr>
    <tr>
      <td>If we were unable to continue to <font color="blue">comply with</font> the new rules, we could be     delisted  from  trading  on the NASDAQ National Market, or Nasdaq, and     thereafter trading in our <font color="blue">common stock</font>, if any, would be conducted through     the over-the-counter market or on the Electronic Bulletin Board of the NASD     As a consequence of such delisting, an investor would likely find it more     <font color="blue">difficult</font> to dispose of, or to obtain <font color="blue">quotations as</font> to the price of, our     <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td><font color="blue">Delisting </font>of our <font color="blue">common stock</font> could also result in lower     prices per share of our <font color="blue">common stock</font> than would otherwise prevail</td>
    </tr>
    <tr>
      <td>Anti-takeover provisions in our <font color="blue">charter documents</font>, our Stockholder Rights     Plan and <font color="blue">Delaware </font>law <font color="blue">may prevent</font> or <font color="blue">delay removal</font> of incumbent <font color="blue">management</font>     or a change of control</td>
    </tr>
    <tr>
      <td>Anti-takeover  provisions  of  our amended and <font color="blue">restated certificate</font> of     in<font color="blue">corporation</font> and amended and <font color="blue">restated bylaws</font>, our <font color="blue">Stockholder Rights Plan </font>    and <font color="blue">Delaware </font>law may have the effect of deterring or <font color="blue">delaying attempts by</font>     our <font color="blue">stockholders</font> to remove or replace <font color="blue">management</font>, engage in <font color="blue">proxy contests</font>     and effect changes in control</td>
    </tr>
    <tr>
      <td>The provisions of our <font color="blue">charter documents</font>     include:           •   a <font color="blue">classified board</font> so that only one of the <font color="blue">three classes</font> of <font color="blue">directors</font>     on our board of <font color="blue">directors</font> is <font color="blue">elected each year</font>;           •   <font color="blue">elimination</font> of <font color="blue">cumulative voting</font> in the election of <font color="blue">directors</font>;           •   procedures for <font color="blue">advance notification</font> of <font color="blue">stockholder nominations</font> and     proposals;           •   the ability of our board of <font color="blue">directors</font> to amend our <font color="blue">bylaws without</font>     <font color="blue">stockholder approval</font>; and           •   the ability of our board of <font color="blue">directors</font> to issue up to 10cmam000cmam000 shares     of preferred stock without <font color="blue">stockholder approval</font> upon the terms and     <font color="blue">conditions</font> and with the rights, privileges and <font color="blue">preferences</font> as our board of     <font color="blue">directors</font> may determine</td>
    </tr>
    <tr>
      <td>The  <font color="blue">rights issued pursuant</font> to our <font color="blue">Stockholder Rights Plan </font>will become     exercisable, subject to <font color="blue">certain exceptions</font>, the tenth day after a person or     group announces <font color="blue">acquisition</font> of 15prca or more of our <font color="blue">common stock</font> or announces     <font color="blue">commencement</font> of a tender or <font color="blue">exchange offer</font> the <font color="blue">consummation</font> of <font color="blue">which would</font>     result in <font color="blue">ownership by</font> the person or group of 15prca or more of our common     stock</td>
    </tr>
    <tr>
      <td>In addition, as a <font color="blue">Delaware </font><font color="blue">corporation</font>, we are subject to <font color="blue">Delaware </font>law,     including Section 203 of the <font color="blue">Delaware </font>General Corporation Law</td>
    </tr>
    <tr>
      <td>In general,     Section 203 prohibits a <font color="blue">Delaware </font><font color="blue">corporation</font> from engaging in any business     <font color="blue">combination with</font> any <font color="blue">interested stockholder</font> for a period of <font color="blue">three years</font>     following the date that the <font color="blue">stockholder became</font> an <font color="blue">interested stockholder</font>     unless certain specific <font color="blue">requirements</font> are <font color="blue">met as set forth</font> in Section 203</td>
    </tr>
    <tr>
      <td>These provisions, alone or together, could have the effect of deterring or     delaying changes in incumbent <font color="blue">management</font>, <font color="blue">proxy contests</font> or changes in     control</td>
    </tr>
    <tr>
      <td>23     ______________________________________________________________________    [46]Table of <font color="blue">Contents       </font>Volatility  in  the  stock prices of other <font color="blue">companies may contribute</font> to     <font color="blue">volatility</font> in our stock price</td>
    </tr>
    <tr>
      <td>The <font color="blue">stock market</font> in general, Nasdaq and the market for <font color="blue">technology</font> companies     in particular, have experienced <font color="blue">significant</font> price and <font color="blue">volume <font color="blue">fluctuations</font></font>     that  have  often  <font color="blue">been unrelated</font> or <font color="blue">disproportionate</font> to the operating     performance  of  those  companies</td>
    </tr>
    <tr>
      <td>Further, there has <font color="blue">been particular</font>     <font color="blue">volatility</font> in the <font color="blue">market price</font>s of securities of <font color="blue">early stage life sciences</font>     companies</td>
    </tr>
    <tr>
      <td>These <font color="blue">broad market</font> and <font color="blue">industry factors may seriously harm</font> the     <font color="blue">market price</font> of our <font color="blue">common stock</font>, <font color="blue">regardless</font> of our operating performance</td>
    </tr>
    <tr>
      <td>In  the past, following periods of <font color="blue">volatility</font> in the <font color="blue">market price</font> of a     company’s securities, securities class action <font color="blue">litigation</font> has often been     instituted</td>
    </tr>
    <tr>
      <td>A securities class <font color="blue">action suit against us could</font> result in     substantial costs, potential <font color="blue">li<font color="blue">abilities</font></font> and the diversion of <font color="blue">management</font>’s     attention and resources</td>
    </tr>
    <tr>
      <td>Our  share  ownership is <font color="blue">concentrated</font>, and our officers, <font color="blue">directors</font> and     principal <font color="blue">stockholders</font> can exert <font color="blue">significant</font> control over matters requiring     <font color="blue">stockholder approval</font></td>
    </tr>
    <tr>
      <td>Due to their combined stock holdings, our officers, <font color="blue">directors</font> and principal     <font color="blue">stockholders</font> (<font color="blue">stockholders</font> holding greater than 5prca of our <font color="blue">common stock</font>)     acting <font color="blue">collectively</font> may have the ability to exercise <font color="blue">significant</font> influence     over  matters requiring <font color="blue">stockholder approval</font> including the election of     <font color="blue">directors</font> and approval of <font color="blue">significant</font> corporate <font color="blue">transactions</font></td>
    </tr>
    <tr>
      <td>In addition,     this <font color="blue">concentration</font> of <font color="blue">ownership may delay</font> or prevent a change in control of     the Company and may make some <font color="blue">transactions</font> more <font color="blue">difficult</font> or impossible to     complete without the support of these <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>Publicly available information regarding <font color="blue">stockholders</font>’ ownership may not be     <font color="blue">comprehensive</font> because the SEC does not require certain large <font color="blue">stockholders</font> to     publicly disclose their <font color="blue">stock ownership positions</font></td>
    </tr>
    <tr>
      <td>Our  operating  results <font color="blue">may fluctuate from quarter</font> to quarter and this     <font color="blue">fluctuation may</font> cause our stock price to decline</td>
    </tr>
    <tr>
      <td>Factors <font color="blue">contributing</font> to these <font color="blue">fluctuations</font>     include, among other items, the timing and <font color="blue">enrollment</font> rates of clinical     trials for our drug <font color="blue">candidates</font>, our need for <font color="blue">clinical supplies</font> and the     valuation of stock-based compensation</td>
    </tr>
    <tr>
      <td>Thus, quarter-to-quarter comparisons     of our operating results are not <font color="blue">indicative</font> of what we might expect in the     future</td>
    </tr>
    <tr>
      <td>As a result, in some future quarters our clinical, financial or     operating results may not meet the <font color="blue">expectations</font> of securities analysts and     investors that could result in a decline in the price of our stock</td>
    </tr>
    <tr>
      <td>There may not be an active, liquid trading market for our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>There is no guarantee that an <font color="blue">active trading market</font> for our <font color="blue">common stock</font>     will be maintained on Nasdaq</td>
    </tr>
    <tr>
      <td><font color="blue">Investors </font>may not be able to sell their shares     quickly or at the <font color="blue">latest <font color="blue">market price</font></font> if trading in our stock is not active</td>
    </tr>
  </tbody>
</table>